Business and Finance

Company pitches a mfr-payer-provider-patient collaboration for drug pricing

Acquisitions jump BMS and Takeda into Top 10; Amgen and Gilead fall out

Guidance for companies starting out on the commercialization path

Guidance for companies starting out on the commercialization path

The PBMs’ new trend toward controlling the flow of funds for patient support is raising questions

Former J&J executive will be the organization’s third-ever leader

Milken Institute survey finds nearly 300 therapies and vaccines

Carving out CGTs for payment systems involving government intervention may be an answer

Revenue leakage in contracting and sales execution affects 95% of respondents

Acquisition of Cumberland Life Sciences boosts its client base and range of services

Now a Danaher Corp. asset, the former GE Healthcare Life Sciences business has been reshuffled

Newly initiated trials may prove value—but even then, supplies may be limited, and hoarding is already occurring

US list-price sales reached $510 billion in 2019

Copenhagen, Denmark tops Boyd Co.’s list with the highest annual operating costs

But: the growth number of companies is exceeding the growth of trials

The big question is how well will the system respond to spikes in demand, and lack of product

PCMA study disputes its members’ harm to brick-and-mortar businesses

ICER will expand use of RWE, as the Federal ONC calls for broader use of healthcare data

Deal with Evoke Pharmaceuticals anticipates FDA approval

Too many states have opted out of the $18-billion agreement being negotiated in federal court

A former executive at PhRMA, Davis will now lead the wholesaler-distributor association

French health-products distributor EHDH will acquire the asset

Thermo Fisher to provide manufacturing expertise

ARM-sponsored study projects a 23% reduction in the cost of treating blood diseases in 2029 by administering cellular and genetic therapies

Trump administration drops its bombshell proposal to open up the US pharmaceutical market

The ‘broken promise’ of lower-cost insulin, according to Senators Warren and Blumenthal

Higher inventory turns, lower inventories—but lower profit margins, too